The FDA has issued 30 warning letters to telehealth companies for making false and misleading claims about compounded products with GLP-1 receptor agonists. These letters focus mainly on claims suggesting sameness with original medicines. According to other sources, the FDA sent more than 55 warning letters in September 2025 to sellers of compounded versions of GLP-1 drugs such as semaglutide (Wegovy, Ozempic) and tirzepatid (Zepbound, Mounjaro). The agency plans to restrict active pharmaceutical ingredients for unapproved compounded products due to misleading marketing. It warns against fake labels, where pharmacies may not exist on the packaging or have not produced the products. Undesirable effects such as redness, swelling, pain at the injection site, nausea, vomiting or hospitalizations caused by incorrect dosing have been reported. Retatrutide and cagrilintide must not be used with compounded medicines because they are not part of approved medicines. The FDA is threatening legal action, including seizure and ban.